

February 14, 2025

To, BSE Limited , 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd. , Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
---	--

Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”)

Dear Sir/Madam,

This has reference to our intimation dated February 6, 2025.

This is to inform you that the Board of Directors, at its meeting held today i.e. on Friday, February 14, 2025, inter alia, approved the following:

- a) Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2024. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The same are also being uploaded on the Company’s Website (<https://www.camlinfs.com/>). The said Results shall be published in newspapers as per the Listing Regulations.
- b) Notice of Postal Ballot for appointment of Mr. Abeezar Faizullahoy as Independent Director and Modification of the Employee Stock Option Scheme 2021.

The Board meeting commenced at 02:00 p.m. (IST) and concluded at 03:50 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary
& VP - Legal



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTH ENDED DECEMBER 31, 2024

(Rs.in Lakh, except per share data)

PARTICULARS	STANDALONE						CONSOLIDATED					
	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	20,507.10	22,691.18	18,560.67	61,389.50	55,293.24	77,326.21	43,349.04	42,297.15	38,586.62	125,231.52	121,136.82	161,306.20
2 Other income	681.73	308.13	212.59	1,167.87	1,333.06	1,888.26	133.62	1,209.69	166.42	466.01	979.26	1,555.64
3 Total income	21,188.83	22,999.31	18,773.26	62,557.37	56,626.30	79,214.47	43,482.66	43,506.84	38,755.04	125,717.53	122,116.08	162,861.84
4 Expenses												
Cost of materials consumed	10,644.57	15,105.32	10,372.23	38,919.60	31,796.46	42,628.92	17,325.68	22,306.05	15,618.85	61,086.00	60,993.40	74,661.46
Purchase of stock in trade	48.25	1,362.71	101.83	1,637.08	457.52	845.85	4,539.94	5,392.86	3,901.88	11,517.06	7,094.71	11,425.87
Changes in inventories of finished goods/WIP/stock in trade	(563.39)	(3,405.54)	287.61	(7,165.32)	(4,388.31)	891.99	(234.01)	(5,791.54)	1,739.55	(7,260.56)	(2,888.84)	5,274.78
Employee benefits expense	1,718.20	1,959.58	1,622.62	5,359.10	4,940.66	6,594.84	5,195.93	5,227.52	4,548.74	15,941.24	13,257.76	17,874.77
Finance costs	1,714.51	1,791.76	1,330.14	4,968.00	4,045.03	5,432.60	3,412.42	2,642.13	1,413.90	8,391.98	4,413.69	6,030.49
Depreciation and amortisation expense	1,326.22	1,343.64	1,240.06	3,939.18	3,660.70	4,939.00	1,447.99	2,069.14	2,057.91	5,528.28	5,856.02	7,860.61
Other expenses	7,019.94	6,268.75	5,587.69	18,905.80	17,209.28	23,651.67	11,642.55	10,837.99	10,447.21	32,286.74	33,963.12	44,677.81
Total Expenses	21,908.30	24,426.22	20,542.18	66,463.44	57,721.34	84,984.87	43,330.50	42,684.15	39,728.04	127,090.74	122,689.86	167,805.79
5 Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)	(719.47)	(1,426.91)	(1,768.92)	(3,906.07)	(1,095.04)	(5,770.40)	152.16	822.69	(973.00)	(1,373.21)	(573.78)	(4,943.95)
6 Exceptional items (Refer Note 8)	-	9,626.66	-	9,626.66	-	192.84	-	15,103.90	-	15,103.90	-	4,980.40
7 Profit / (Loss) before share of profit / (loss) of associate (5-6)	(719.47)	(11,053.57)	(1,768.92)	(13,532.73)	(1,095.04)	(5,963.24)	152.16	(14,281.21)	(973.00)	(16,477.11)	(573.78)	(9,924.35)
8 Share of profit / (loss) of associate	-	-	-	-	-	-	(184.89)	50.50	-	(134.39)	-	-
9 Profit / (Loss) before tax (7-8)	(719.47)	(11,053.57)	(1,768.92)	(13,532.73)	(1,095.04)	(5,963.24)	(32.73)	(14,230.71)	(973.00)	(16,611.50)	(573.78)	(9,924.35)
10 Tax Expenses												
- Current tax (Refer Note 9)	-	544.25	(133.12)	165.97	62.81	-	432.28	1,641.48	648.34	2,813.64	1,835.81	2,487.23
- Deferred tax	(156.75)	(4,335.66)	(471.70)	(4,505.81)	(426.23)	(824.32)	282.14	(4,261.41)	(193.61)	(3,602.19)	(100.59)	(1,924.07)
11 Profit / (Loss) for the period (9-10)	(562.72)	(7,262.16)	(1,164.10)	(9,192.89)	(731.62)	(5,138.92)	(747.15)	(11,610.78)	(1,427.73)	(15,822.95)	(2,309.00)	(10,487.51)
12 Other comprehensive income												
A Items that will not be reclassified to profit or loss												
(i) Remeasurements of defined benefit plans	8.60	(23.79)	8.69	(30.76)	(6.50)	(8.54)	8.60	(23.79)	8.69	(30.76)	(6.50)	(9.07)
(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.00)	8.31	(3.04)	10.75	2.27	2.98	(3.00)	8.31	(3.04)	10.75	2.27	2.98
B Items that will be reclassified to profit or loss												
(i) Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	(978.52)	74.08	1,647.63	(1,554.61)	1,870.68	1,801.40
(ii) The effective portion of gain or loss on hedging instruments in a cash flow hedge	(365.41)	(86.16)	(14.67)	(350.99)	34.21	1.70	(365.41)	(86.16)	(14.67)	(350.99)	34.21	1.70
(iii) Income tax relating to items that will be reclassified to profit or loss	127.69	30.11	0.26	122.65	(11.95)	(0.60)	127.69	30.11	0.26	122.65	(11.95)	(0.60)
Other comprehensive income	(232.12)	(71.53)	(8.76)	(248.35)	18.03	(4.46)	(1,210.64)	2.55	1,638.87	(1,802.96)	1,888.71	1,796.41
13 Total comprehensive income for the period (11+12)	(794.84)	(7,333.69)	(1,172.86)	(9,441.24)	(713.59)	(5,143.38)	(1,957.79)	(11,608.23)	211.14	(17,625.91)	(420.29)	(8,691.10)
14 Profit / (Loss) attributable to:												
(i) Owners of the Company							(413.63)	(10,023.16)	(1,178.56)	(13,832.20)	(1,561.40)	(9,275.34)
(ii) Non-controlling interests							(333.52)	(1,587.62)	(249.17)	(1,990.75)	(747.60)	(1,212.17)
15 Other comprehensive income attributable to:												
(i) Owners of the Company							(1,115.95)	24.30	1,621.74	(1,737.58)	1,919.87	1,835.36
(ii) Non-controlling interests							(94.69)	(21.75)	17.13	(65.38)	(31.16)	(38.95)
16 Total comprehensive income attributable to:												
(i) Owners of the Company							(1,529.58)	(9,998.86)	443.18	(15,569.78)	358.47	(7,439.98)
(ii) Non-controlling interests							(428.21)	(1,609.37)	(232.04)	(2,056.13)	(778.76)	(1,251.12)
17 Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65
18 Other Equity						69,896.75						84,800.43
19 Earnings per Share (EPS) (of Re.1/-each) (not annualised) (Refer Note 6)												
Basic (Rs.)	(0.33)	(4.26)	(0.68)	(5.40)	(0.43)	(3.04)	(0.24)	(5.89)	(0.69)	(8.12)	(0.93)	(5.49)
Diluted (Rs.)	(0.33)	(4.22)	(0.67)	(5.35)	(0.43)	(3.00)	(0.24)	(5.83)	(0.68)	(8.04)	(0.91)	(5.41)

ANNEXURE 1



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Sankhraj (East), Mumbai 400 098.
CIN: L74100MH1993PLCC083971



+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

Notes to Unaudited Financial Results:

1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2025. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. The Statutory Auditors of the Company have carried out Limited Review of these financial results.

2 Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED			NINE MONTH ENDED			QUARTER ENDED			NINE MONTH ENDED		
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Exchange gain	536.09	181.16	62.80	733.08	453.18	541.51	-	1,044.06	-	-	-	-
Exchange loss	-	-	-	-	-	-	439.87	-	921.67	423.06	2,174.10	3,946.68
Total Exchange gain / (loss)	536.09	181.16	62.80	733.08	453.18	541.51	(439.87)	1,044.06	(921.67)	(423.06)	(2,174.10)	(3,946.68)

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

3 Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED			NINE MONTH ENDED			QUARTER ENDED			NINE MONTH ENDED		
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Exchange gain	-	-	-	-	-	-	-	-	207.33	-	351.19	419.58
Exchange loss	431.46	113.44	20.74	566.94	146.63	168.78	1,782.11	524.66	-	2,943.71	-	-
Total Exchange gain / (loss)	(431.46)	(113.44)	(20.74)	(566.94)	(146.63)	(168.78)	(1,782.11)	(524.66)	207.33	(2,943.71)	351.19	419.58

4 During the quarter ended December 31, 2024, the Company has not allotted any shares under Employees Stock Option Scheme, 2018 (ESOP-2018) and Employees' Stock Option Scheme, 2020 (ESOP-2020). 1400 employee stock options have lapsed under ESOP-2018 during the quarter ended December 31, 2024. No employee stock options have lapsed under ESOP-2020 during the quarter ended December 31, 2024.

5 The Board of Directors of the Company and the Shareholders at their respective meetings held on September 10, 2024 and October 18, 2024, approved the increase in Authorised Capital of the Company to Rs. 21,50,00,000/- (21,50,00,000 equity shares of Re. 1/- each) from Rs. 18,00,00,000/- (18,00,00,000 equity shares of Re. 1/- each).

6 On November 22, 2024, the Board of Directors of the Company, approved the right issue of equity shares for an amount upto Rs. 225,00,00,000/-. Pursuant to it, the Securities Issue and Allotment Committee of the Board at its meeting held on January 8, 2025 declared a right issue of 2,04,26,244 equity shares of Re 1 each for a subscription of Rs. 110 per share (along with a share premium of Rs. 109 per equity share) aggregating to Rs. 224,66,86,840/- for a right entitlement of 5 right equity shares for 41 equity shares. The Securities Issue and Allotment Committee of the Board at its meeting held on January 31, 2025, took on record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful applicants for a total amount of Rs. 2,24,68,38,550. The aforesaid allotment does not include the entitlements of 439 Rights Equity Shares which have been kept in abeyance. Basic and Diluted EPS are recalculated to give effect of the right issue in all reporting periods in accordance with IND AS 33 (Earnings Per Share)

7 On June 11, 2024, wholly owned subsidiary of the company, Dresen Quimica SAPI De CV, Mexico, has acquired entire stake in Vitafor Invest NV, Belgium at a consideration of Euro 1. Vitafor Invest NV has wholly owned subsidiaries/associate namely Addi-Tech NV (100%); Vitafor NV (100%); Vitafor China Ltd. (100%); Europe Bio Engineering BV (100%) and Vial Srl (45%) (collectively known and referred as "Vitafor Group"). The consolidated financial statements include the unaudited results of Vitafor Group for the period June 11, 2024, to December 31, 2024.

8 The exceptional Items, expense (net) recognised in Profit and Loss in the quarter ended September 30, 2024 includes:

I. In the standalone financial results:

i) Impairment loss on investments in subsidiaries namely:

a. CFS Europe Rs. 1,178.56 Lakh

b. CFSWL Rs. 436.92 Lakh (Previous year ended 31.03.2024 Rs. 192.84 Lakh)

c. CFS Pahang Asia Pte Ltd Rs. 17.90 Lakh

ii) Impairment of trade and other receivables (net of payables) due from subsidiaries:

a. CFS Europe Sp A Rs. 1,929.04 Lakh

b. CFSWL Rs. 5,886.89 Lakh

iii) Loss on demolition / refurbishment of assets Rs. 177.35 Lakh

II. In the consolidated financial results:

i) Impairment of Property Plant and Equipment, Intangibles and certain other assets:

a. Relating to CGU of Diphenol facility at CFS Europe Sp A Rs. 11,649.14 Lakh (Net of adjustment to Revaluation Reserve Rs. 3,499.23 Lakh) (Previous year ended 31.03.2024 Inventory write off Rs. 2,279.56 Lakh)

b. Relating to CFSWL Rs. 1,875.24 Lakh (Previous year ended 31.03.2024 Rs. 2,700.84 Lakh)

c. Derecognition of deferred taxes of CFSWL Rs. 1,157.40 Lakh

ii) Acquisition related costs of Vitafor Group Rs. 201.72 Lakh

iii) Loss on demolition / refurbishment of assets Rs. 220.39 Lakh

9 Current Tax for Nine month ended December 31, 2024 includes tax provision relating to earlier years amounting to Rs. 165.97 Lakh.

10 The Company's operations constitute a single business segment in Speciality Chemicals.

Place: Mumbai
Date: February 14, 2025



For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379



CFS[®]
Camlin
Fine Sciences

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

The Board of Directors
Camlin Fine Sciences Limited


LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Unaudited Standalone Financial Results of **Camlin Fine Sciences Limited** ("the Company") for the quarter and nine months period ended December 31, 2024, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") duly initialled by us for identification.
- 2) This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on February 14, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kalyaniwalla & Mistry LLP

Chartered Accountants

Firm Registration No.: 104607W/WI00166



Anil A. Kulkarni

Partner

Membership No.: 047576

UDIN: 25047576BMKXFV9267

Place: Mumbai

Date: February 14, 2025



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

The Board of Directors
Camlin Fine Sciences Limited

LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Unaudited Consolidated Financial Results of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit / (loss) after tax and total comprehensive income of an associate company of its subsidiary company (refer paragraph 4 below) for the quarter and nine months period ended December 31, 2024 together with the notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations") duly initialled by us for identification.
- 2) This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by Parent's Board of Directors, at their respective meetings held on February 14, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

- 4) The Statement includes the results of the following entities:

Incorporated In India

Sr. No.	Name of the Entity	Relationship
I	Chemolutions Chemicals Ltd.	Subsidiary
Ii	AlgalR Nutra Pharms Private Limited	Subsidiary



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

Incorporated Outside India

Sr. No.	Name of the Entity	Relationship
i.	CFS North America LLC	Wholly owned subsidiary
ii.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
iii.	Solentus North America Inc	Wholly owned subsidiary
iv.	CFS Europe S.P.A	Wholly owned subsidiary
v.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vi.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
vii.	Nuvel, S.A.C.	Step down subsidiary
viii.	Britec, S.A.	Step down subsidiary
ix.	Inovel, S.A.S	Step down subsidiary
x.	Grinel, S.R.L	Step down subsidiary
xi.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xii.	CFS Pahang Asia Pte. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS De Mexico Blends, S.A.P.I DE CV	Wholly owned subsidiary
xvi.	CFS PP (M) SDN. BHD	Subsidiary
xvii.	Vitafor Invest NV, Belgium (w.e.f. June 11, 2024)	Step down subsidiary
xviii.	Vitafor NV (w.e.f. June 11, 2024)	Step down subsidiary
xix.	Addi-Tech NV (w.e.f. June 11, 2024)	Step down subsidiary
xx.	Vitafor China Ltd. (w.e.f. June 11, 2024)	Step down subsidiary
xxi.	Europe Bio Engineering BV (w.e.f. June 11, 2024)	Step down subsidiary
xxii.	Vial SARL (w.e.f. June 11, 2024)	Associate Company of a Step down subsidiary

5) Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) Other Matters:

A. We did not review the interim financial results of 16 subsidiaries incorporated outside India and 2 subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total revenues of Rs. 32,949.84 Lakh and Rs.90,406.98 Lakh for the quarter and for the nine months period ended December 31, 2024, respectively, Group's share of total net profit / (loss) after tax of Rs. (3,181.02) Lakh and Rs.(3,888.01) Lakh and total comprehensive income of Rs. (3,900.53) Lakh and Rs. (5,761.26) Lakh for the quarter and nine months period ended December 31, 2024, respectively.

The Statement also includes the Group's share of net profit/ (loss) after tax and total comprehensive income of Rs. (184.89) Lakh and Rs (134.39) Lakh for the quarter and nine months period ended respectively as considered in the consolidated unaudited financial results, in respect of an associate of a subsidiary, located outside India.



These interim financial results of the subsidiaries and associate as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


In respect of these subsidiaries (including an associate) located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which has been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries (including an associate) located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Parent's Management.

- B. The Statement includes interim financial results of 5 subsidiaries incorporated outside India which have not been reviewed and have been included on the basis of the Unaudited Management Accounts, whose interim financial results reflect Group's share of total revenues of Rs.419.67 Lakh and Rs. 1,426.53 Lakh for the quarter and nine months period ended December 31, 2024, respectively, Group's share of total net profit / (loss) after tax of Rs. 222.65 Lakh and Rs.(391.90) Lakh and total comprehensive income of Rs. (27.91) Lakh and Rs. 23.12 Lakh for the quarter and nine months period ended December 31, 2024, respectively.

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For Kalyaniwalla & Mistry LLP
Chartered Accountants
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 25047576BMKXFW7422
Place: Mumbai
Date: February 14, 2025





For Camlin Fine Sciences Limited

Ashish S. Dandekar

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTH ENDED DECEMBER 31, 2024													
												(Rs.in Lakh, except per share data)	
No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	20,507.10	22,691.18	18,560.67	61,389.50	55,293.24	77,326.21	43,349.04	42,297.15	38,588.62	125,231.52	121,136.82	161,306.20
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(719.47)	(1,426.91)	(1,768.92)	(3,906.07)	(1,095.04)	(5,770.40)	(32.73)	873.19	(973.00)	(1,507.60)	(573.78)	(4,943.95)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(719.47)	(11,053.57)	(1,768.92)	(13,532.73)	(1,095.04)	(5,963.24)	(32.73)	(14,230.71)	(973.00)	(16,611.50)	(573.78)	(9,924.35)
4	Net Profit / (Loss) for the period after tax (after exceptional items)	(562.72)	(7,262.16)	(1,164.10)	(9,192.89)	(731.62)	(5,138.92)	(747.15)	(11,610.78)	(1,427.73)	(15,822.95)	(2,309.00)	(10,487.51)
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)							(413.63)	(10,023.16)	(1,178.56)	(13,832.20)	(1,561.40)	(9,275.34)
6	Total Comprehensive Income for the period	(794.84)	(7,333.69)	(1,172.86)	(9,441.24)	(713.59)	(5,143.38)	(1,957.79)	(11,608.23)	211.14	(17,625.91)	(420.29)	(8,691.10)
7	Equity Share Capital	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65
8	Other Equity				-	-	69,896.75				-	-	84,800.43
9	Earnings per share (of Re 1/-each) (not annualised)												
	-Basic Rs.	(0.33)	(4.26)	(0.68)	(5.40)	(0.43)	(3.04)	(0.24)	(5.89)	(0.69)	(8.12)	(0.93)	(5.49)
	-Diluted Rs.	(0.33)	(4.22)	(0.67)	(5.35)	(0.43)	(3.00)	(0.24)	(5.83)	(0.68)	(8.04)	(0.91)	(5.41)

1 The above information is an extract of the detailed format of unaudited results for the quarter ended December 31, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter December 31, 2024 are available on the Company's website at www.camlins.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

Place: Mumbai
Date: February 14, 2025

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlins.com



www.camlins.com